Skip to main content
NCBI home page
AAPS PharmSciTech logoLink to AAPS PharmSciTech
. 2007 Apr 13;8(2):E25–E31. doi: 10.1208/pt0802030

Floating granules of ranitidine hydrochloride-gelucire 43/01: Formulation optimization using factorial design

Dasharath M Patel 1,✉, Natavarlal M Patel 1, Viral F Patel 1, Darshini A Bhatt 1
PMCID: PMC2750366  PMID: 17622108

Abstract

The purpose of this research was to develop and optimize a controlled-release multiunit floating system of a highly water soluble drug, ranitidine HCl, using Compritol, Gelucire 50/13, and Gelucire 43/01 as lipid carriers. Ranitidine HCl-lipid granules were prepared by the melt granulation technique and evaluated for in vitro floating and drug release. ethyl cellulose, methylcellulose, and hydroxypropyl methylcellulose were evaluated as release rate modifiers. A 32 full factorial design was used for optimization by taking the amounts of Gelucire 43/01 (X1) and ethyl cellulose (X2) as independent variables, and the percentage drug released in 1(Q1), 5(Q5), and 10 (Q10) hours as dependent variables. The results revealed that the moderate amount of Gelucire 43/01 and ethyl cellulose provides desired release of ranitidine hydrochloride from a floating system. Batch F4 was considered optimum since it contained less Gelucire and was more similar to the theoretically predicted dissolution profile (f2=62.43). The temperature sensitivity studies for the prepared formulations at 40°C/75% relative humidity for 3 months showed no significant change in in vitro drug release pattern. These studies indicate that the hydrophobic lipid Gelucire 43/01 can be considered an effective carrier for design of a multiunit floating drug delivery system for highly water soluble drugs such as ranitidine HCl.

Keywords: Multiunit lipid granules, Gelucire, ranitidine hydrochloride, floating

Full Text

The Full Text of this article is available as a PDF (259.3 KB).

References

  • 1.Iannuccelli V, Coppi G, Bernabei MT, Cameroni R. Air compartment multiple-unit system for prolonged gastric residence, Part I: formulation study. Int J Pharm. 1998;174:47–54. doi: 10.1016/S0378-5173(98)00229-4. [DOI] [Google Scholar]
  • 2.Santus G, Lazzarini G, Bottoni G, et al. Anin vitro-in vivo investigation of oral bioadhesive controlled release furosemide formulations. Eur J Pharm Biopharm. 1997;44:39–52. doi: 10.1016/S0939-6411(97)00100-8. [DOI] [Google Scholar]
  • 3.Deshpande AA, Rhodes CT, Shah NH, Malick AW. Controlled-release drug delivery systems for prolonged gastric residence: an overview. Drug Dev Ind Pharm. 1996;22:531–539. doi: 10.3109/03639049609108355. [DOI] [Google Scholar]
  • 4.Deshpande AA, Shah NH, Rhodes CT, Malick W. Development of a novel controlled-release system for gastric retention. Pharm Res. 1997;14:815–819. doi: 10.1023/A:1012171010492. [DOI] [PubMed] [Google Scholar]
  • 5.Menon A, Ritschel WA, Sakr A. Development and evaluation of a monolithic floating dosage form for furosemide. J Pharm Sci. 1994;83:239–245. doi: 10.1002/jps.2600830225. [DOI] [PubMed] [Google Scholar]
  • 6.Whitehead L, Fell JT, Collett JH, Sharma HL, Smith AM. Floating dosage forms: an in vivo study demonstrating prolonged gastric retention. J Control Release. 1998;55:3–12. doi: 10.1016/S0168-3659(97)00266-6. [DOI] [PubMed] [Google Scholar]
  • 7.Park K, Park H. Enzyme digestible balloon hydrogel for long term oral drug delivery: synthesis and characterization. Int Symp Rel Bioact Mater. 1987;14:41–42. [Google Scholar]
  • 8.Ch'Ng HS, Park H, Kelly P, Robinson JR. Bioadhesive polymers as platforms for oral controlled drug delivery, II: synthesis and evaluation of some swelling water-insoluble bioadhesive polymers. J Pharm Sci. 1985;74:399–405. doi: 10.1002/jps.2600740407. [DOI] [PubMed] [Google Scholar]
  • 9.Kaniwa N, Aoyagi N, Ogata H, Ejima A. Gastric emptying of enteric coated drug preparations, II: effect of size and density of enteric coated drug preparations and food on gastric emptying rates in humans. J Pharmacobiodyn. 1988;11:571–575. doi: 10.1248/bpb1978.11.571. [DOI] [PubMed] [Google Scholar]
  • 10.Efentakis M, Koutlis A, Vlachou M. Development and evaluation of oral multiple-unit and single-unit hydrophilic controlled-release systems. AAPS PharmSciTech. 2000;1:E34–E34. doi: 10.1208/pt010434. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Dennis AB, Farr SJ, Kellaway IW, Taylor G, Davidson R. In vivo evaluation of rapid release and sustained release Gelucire capsule formulations. Int J Pharm. 1990;65:85–100. doi: 10.1016/0378-5173(90)90013-T. [DOI] [Google Scholar]
  • 12.Remunan C, Bretal M, Nunez A, Bila Jato JL. Accelerated stability of sustained release tablet prepared with Gelucire. Int J Pharm. 1992;80:151–159. doi: 10.1016/0378-5173(92)90273-5. [DOI] [Google Scholar]
  • 13.Saraiya D, Bolton D. The use of Precirol to prepare sustained release tablets of theophylline and quinidine gluconate. Drug Dev Ind Pharm. 1990;16:1963–1969. doi: 10.3109/03639049009023634. [DOI] [Google Scholar]
  • 14.Li S, Lin S, Chien YW, Daggy BP, Mirchandani HL. Statistical optimization of gastric floating system for oral controlled delivery of calcium. AAPS PharmSciTech. 2001;2:E1–E1. doi: 10.1208/pt020101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Kumar MK, Shah MH, Ketkar A, Mahadik KR, Paradkar A. Effect of drug solubility and different excipients on floating behavior and release from glyceryl monooleate matrices. Int J Pharm. 2004;272:151–160. doi: 10.1016/j.ijpharm.2003.12.025. [DOI] [PubMed] [Google Scholar]
  • 16.Aïnaoui A, Vergnaud JM. Modelling the plasma drug level with oral controlled release forms with lipidic Gelucire. Int J Pharm. 1998;169:155–162. doi: 10.1016/S0378-5173(98)00105-7. [DOI] [Google Scholar]
  • 17.Sheu MT, Hsia AHO. Polyglycolized saturated glycerides as carrier and enhancer for drug penetration. Chin Pharm J. 2001;53:107–111. [Google Scholar]
  • 18.Barker SA, Yap SP, Yuen KH, McCoy CP, Murphy JR, Craig DQM. An investigation into the structure and bioavailability of α-tocopherol dispersion in Gelucire 44/14. J Control Release. 2003;91:477–488. doi: 10.1016/S0168-3659(03)00261-X. [DOI] [PubMed] [Google Scholar]
  • 19.Sutananta W, Craig DQM, Newton JM. An evaluation of the mechanisms of drug release from glyceride bases. J Pharm Pharmacol. 1995;47:182–187. doi: 10.1111/j.2042-7158.1995.tb05775.x. [DOI] [PubMed] [Google Scholar]
  • 20.Shimpi S, Chauhan B, Mahadik KR, Paradkar A. Preparation and evaluation of diltiazem hydrochloride-Gelucire 43/01 floating granules prepared by melt granulation. AAPS PharmSciTech. 2004;5:E43–E43. doi: 10.1208/pt050343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Flynn M. Histamine H2 antagonists. In: Hagemann RC, Threlkeld DS, editors. Drug Facts and Comparisons. 50th ed. St Louis, MO: Wolters Kluwer Co; 1996. pp. 1862–1876. [Google Scholar]
  • 22.Somade S, Singh K. Comparative evaluation of wet granulation and direct compression methods for preparation of controlled release ranitidine HCL tablets. Indian J Pharm Sci. 2002;64:285–285. [Google Scholar]
  • 23.Lauritsen K. Clinical pharmacokinetics of drugs used in the treatment of gastro intestinal diseases. Clin Pharmacokinet. 1990;19(11–31):94–125. doi: 10.2165/00003088-199019020-00002. [DOI] [PubMed] [Google Scholar]
  • 24.Grant S. Ranitidine: an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs. 1989;37:801–870. doi: 10.2165/00003495-198937060-00003. [DOI] [PubMed] [Google Scholar]
  • 25.Basit A, Lacey L. Colonic metabolism of ranitidine: implications for its delivery and absorption. Int J Pharm. 2001;227:157–165. doi: 10.1016/S0378-5173(01)00794-3. [DOI] [PubMed] [Google Scholar]
  • 26.Coffin M, Parr A, inventors. Glaxo Inc. Ranitidine solid dosage form. US patent 5 407 687. April 18, 1995.
  • 27.Mendenhall W, Sincich T, editors. Multiple regression. 3rd ed. San Francisco, CA: Dellen Publishing Co; 1989. pp. 141–226. [Google Scholar]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists

RESOURCES